The Goldman Sachs Group, Inc.

🇺🇸New York Stock Exchange
Back to all articles
The Goldman Sachs Group, Inc. stock analysis GS overview
Very Bullish +85

Goldman says stocks like Nvidia have more room to run - CNBC

📈 Goldman Sachs identifies Nvidia, Samsara, BrightSpring Health Services, Ulta Beauty, and Johnson & Johnson as top picks with significant upside.

💊 BrightSpring Health Services receives a Buy rating with a $71 price target from analysts led by Scott Fidel.

🚀 Samsara is described as one of the most defensible growth assets in software with improving profit margins.

💄 Ulta Beauty raised operating income and EPS guidance, prompting Goldman to advise buying the dip at current levels.

📊 Nvidia maintains a Buy rating with Goldman estimates for CY27 standing over 30% above Street consensus.

💉 Johnson & Johnson is highlighted for its $80 billion balance sheet capacity and strengthening innovative medicine business.

🏥 BrightSpring's business model supports a premium growth framework rather than conventional post-acute multiples.

☁️ Samsara's June 24th investor day is flagged as a positive catalyst for the connected operations platform.

📉 Ulta Beauty stock is down 23% this year, but analysts see market share gains fueled by healthy cosmetics demand.

🔬 Goldman expects J&J to continue its track record of augmenting revenue growth in innovative medicines.

Bullish Signals
  • Goldman Sachs explicitly names Nvidia, Samsara, BrightSpring Health Services, Ulta Beauty, and Johnson & Johnson as stocks with 'more room to run' or significant upside.
  • BrightSpring Health Services shares are up 67% in 2026, reflecting strong market confidence in its home health care model.
  • Samsara has improved profit margins and is viewed as a defensible growth asset with a competitive moat.
  • Ulta Beauty raised both operating income growth and EPS guidance following a solid first-quarter performance.
  • Goldman maintains a Buy rating on Nvidia, projecting sustained growth into 2027 with estimates significantly above Street consensus.
  • Johnson & Johnson possesses the industry's highest balance sheet capacity at $80 billion to fund revenue growth in innovative medicines.
  • Analysts believe Ulta Beauty's investments in marketing and service are successfully driving market share gains.
  • Samsara is recommended for purchase on any weakness, indicating a strong buy recommendation from Goldman.
Full Analysis
Goldman Sachs analysts have identified several stocks as well-positioned for growth in the current market environment, highlighting Nvidia, Samsara, BrightSpring Health Services, Ulta Beauty, and Johnson & Johnson. The bank emphasizes that these companies possess defensive qualities alongside significant upside potential, citing strong execution and expanding growth drivers. For BrightSpring Health Services, analysts led by Scott Fidel initiated coverage with a Buy rating and a $71 price target. They praise the company's differentiated offering in home health care, which addresses specialty drug complexity and infusion site-of-care migration. Shares have risen 67% in 2026 as the firm positions itself for premium growth in the aging population sector. Samsara is viewed by analyst Matthew Martino as a defensible growth asset with improving profit margins. Following a solid earnings report, Goldman sees room to run given its expanding growth drivers and upcoming June 24th investor day. The stock has gained 18% over the past month, reinforcing its competitive moat in connected operations cloud platforms. Ulta Beauty is considered best positioned to gain market share after raising operating income and EPS guidance following a strong first quarter. Analyst Kate McShane maintains a $652 price target, implying substantial upside despite a 23% decline year-to-date. Goldman believes the company's investments in marketing and service are fueling comp acceleration through FY26. Goldman reiterates a Buy rating on Nvidia, citing improved capital allocation and sustained growth into 2027 with estimates over 30% above Street consensus. Additionally, Johnson & Johnson is favored for its strengthening pharma franchise and massive $80 billion balance sheet capacity to augment revenue in innovative medicines.